Mar 31, 2013
The Directors have pleasure in presenting the Twenty-fifth Annual
Report together with the Audited Statement of Accounts for the year
ended March 31, 2013
FINANCIAL RESULTS (Rs. in Crores)
Particulars 2012-2013 2011-12
Gross Income 704.46 456.02
Profit before tax 62.55 37.21
Profit after tax 40.61 19.40
Profit available for appropriation (after 90.91 57.54
considering the balance b/f from previous
year and deferred tax liability)
APPROPRIATIONS
Dividend of current year 4.82 3.37
Corporate Dividend Tax 0.78 0.54
Transfer to General Reserve 12.60 1.94
Surplus carried to Balance Sheet 72.71 50.30
Operations and Business Performance
During the year 2012-13, the gross income increased from Rs.456 Crores
to Rs 704 Crores, recording an increase of 54% over the previous year,
while profit before tax has increased from Rs.37.21 Crore to Rs 62.55
Crore showing increase over 68% of last year.
DIVIDEND
Considering the profits and the need to conserve the resources, your
directors recommend a dividend of Re.1 per share (8% dividend forthe
year 2% as special dividend due to Silver Jubilee Year) per share of
Rs.10 each on the paid-up capital of the Company. The outflow on this
account would be Rs 482.30 Lakhs excluding dividend tax.
Consolidated Accounts
In accordance with the requirements of Accounting Standard prescribed
by the Institute of Chartered Accountants of India, the Consolidated
Accounts for the year ended 31st March 2013 under Indian GAAP forms
part of the Annual Report.
Future outlook
The Betalactum Cepharm and Ayurvedic projects are under implementation
and same are expected to be ready for commercial operations by end of
third quarter of currentfinancial year.
During the current year, the Irrungatukottai unit is proposed to be
demerged to Arvind Wellness Ltd. a wholly owned subsidiary and the
company has fixed 8th April 2013 as appointed date based on the
valuation of shares of the scheme and subject to necessary approvals.
In the current year, the company has plans to implement R&D product
development unit at Irrungatukottai unit for ANDAs to be filed for US,
which is expected to involve capital outlay of Rs. 160 Crores.
CHANGES IN CAPITAL STRUCTURE/CONSOLIDATION
During the year, the Company has issued 19896000 convertible equity
warrants at face value of Rs. 10 each and premium of Rs.15 per warrant.
The conversion period is upto July 2014 and on conversion of all the
19896000 warrants into equity, the paid up share capital will stand
increased to Rs.68.12 Crores. In case the option to convert the
warrants to equity shares is not exercised before the expiry date, the
application money of Rs.6.25 received on each warrant will stand
forfeited.
SUBSIDIARY COMPANY
Coronet Labs P Ltd. is a subsidiary company and pursuant to the
provisions of Section 212 of the Companies Act, 1956, the details of
the subsidiary and the consolidated audited accounts of the Company
together with the Auditor''s Report for the year 2012-13are attached
forming partoftheAnnual Report.
During the current year on 8th April 2013 Arvind Wellness Limited has
been incorporated as the wholly owned subsidiary of the company.
DIRECTORS
Pursuant to the provisions of Section 256 of the Companies Act, 1956
and the Articles of Association of the Company, Dr. CMK Reddy and Mr. V
R Mehta Directors of the Company, retire by rotation at the ensuing
Annual General Meeting and being eligible, offer for re-appointment.
Board recommend their reappointment.
During the year Mr. Sudhir Chandra was appointed from 18th December
2012 and Mr. Santhana Raman from 12th February 2013 as Additional
Directors and their term shall expire at the Annual General Meeting.
Mr. Santhana Raman has resigned on 3rd July 2013. Reappointment of Mr.
Sudhir Chandra as director is taken at item No.6 in the notice.
In accordance with the stipulation under Clause 49 of the Listing
Agreement, brief resume of the Directors seeking appointment and
re-appointment at the ensuing Annual General Meeting togetherwith the
nature of their expertise in specific functional areas and names of
companies in which they hold office as Director and/or Chairman/ Member
of Committees of the Board is annexed to the notice.
AUDITORS:
Your company''s Statutory Auditors M/s. Doshi Chatterjee Bagri & Co.
Chartered Accountants shall retire at the conclusion of the ensuing
Annual General Meeting. The Statutory Auditors have confirmed their
eligibility and willingness to accept the office on re-appointment. The
necessary resolution seeking approval of members for re- appointment of
Statutory Auditors has been provided in the Notice convening the Annual
General Meeting.
Auditor''s Report and Notes to Accounts.
The Board has duly reviewed the Statutory Auditors Report on the
Accounts. The Auditors Report is self explanatory and do not call for
any further explanation/ clarification by the Board of Directors under
Section 217(3) of the Companies Act, 1956.
Internal Audit
During the year under review, the Company had engaged M/s.Siva
Anantharaman & Co., Chartered Accountants, Chennai as Internal
Auditors. Due to their resignation from October 2012 the Company has
appointed Mr. R.T. Vijaya Raghavan as the Internal Auditors of the
Company to carry out internal audit on regular basis. The reports of
the Internal audit for the quarters are presented for review before the
Audit Committee. The Audit Committee also scrutinizes all the
programmes and adequacy of the internal audits.
Management Discussion and Analysis (MDA):
The Management Discussion and Analysis Report for the year under
review, as stipulated under Clause 49 of the Listing Agreement is
presented in a separate section forming part of this Annual Report.
CORPORATE GOVERNANCE
The Company complies with the provisions of Corporate Governance as per
the listing agreement with the Stock Exchanges. Aseparate Report on
Corporate Governance is attached which forms part of the Annual Report.
FIXED DEPOSITS
During the year the Company has not accepted any fixed deposits from
the public.
PARTICULARS OF ENERGY CONSERVATION ETC.
The details of energy conservation, technology absorption, foreign
exchange earning and outgo are furnished in a separate statement
attached to and forming part of this report, in accordance with Section
217(1)(e) of the Companies Act, 1956, read with The Companies
(Disclosure of Particulars in the Report of Board of Directors) Rules,
1988.
PARTICULARS OF EMPLOYEES
During the year, the Company did not have any employee drawing
remuneration of amounts specified under Section 217(2A) of the
Companies Act, 1956, read with The Companies (Particulars of Employees)
Rules, 1975 and hence the details are not furnished.
DIRECTORS'' RESPONSIBILITY STATEMENT
Your Directors affirm that the audited accounts containing the
financial statements for the financial year 2012-13 are in conformity
with the requirements of the Companies Act, 1956. They believe that the
financial statements reflect fairly the form and substance of
transactions carried out during the year and reasonably present the
Company''s financial conditions and results of operations.
Pursuance to Section 217(2AA) of the Companies Act, 1956, your
Directors confirm that -
(I) the annual accounts forthe year ended on 31st March 2013 have been
prepared on a going concern basis
(ii) in preparation of the accounts, the applicable accounting
standards have been followed and necessary explanations are given for
material departures, if any
(iii) sound accounting policies have been applied consistently and
judgements and estimates made that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company as on
31st March 2013 and of the Profit of the company for the year ended on
that date and
(iv) proper and sufficient care has been taken for maintenance of
adequate accounting records in accordance with the provisions of the
Companies Act, 1956 for safeguarding the assets of the company and for
prevention and detection of fraud and other irregularities.
LISTING:
The Company''s shares are presently listed at Bombay Stock Exchange Ltd.
and in National Stock Exchange of India Ltd.
ACKNOWLEDGEMENTS
Your Directors wish to place on record their appreciation for the
continued co-operation of the banks and other financial institutions
associated with the company. Your Directors also thank Medical
fraternity for the trust reposed on the Company and the trade, the
stockists and consumers for their patronage to the Company''s products.
Your Directors also place on record their profound admiration and
sincere appreciation of the continued hard work put in by the employees
at all levels. We look forward to the same support in ourfuture
endeavours.
For and on behalf of the Board
Place:Chennai Dr. B. ARVIND SHAH Dr. CHANDRARAVINDRAN
Date : 23.07.2013 Managing Director Whole time Director
Mar 31, 2012
The Directors have pleasure in presenting the Twenty-Fourth Annual
Report together with the Audited Statement of Accounts for the year
ended March 31, 2012
FINANCIAL RESULTS (Rs. in Crores)
Particulars 2011-2012 2010-11
Gross Income 456.02 377.01
Profit before tax 37.21 22.77
Profit after tax 19.40 16.90
Profit available for appropriation
(after considering the 57.54 42.36
balance b/f from previous
year and deferred tax
liability)
APPROPRIATIONS
Dividend of current year 3.37 3.37
Dividend of 2010-11 118.92 -
Dividend tax of 2010-11 19.29 -
Corporate Dividend Tax 0.54 0.54
Transfer to General Reserve 1.94 1.69
Surplus carried to Balance Sheet 50.30 36.76
Operations and Business Performance
During the year 2011 -12, the net sales increased from Rs.362 Crores to
Rs 436 Crores, recording an increase of 21 % over the previous year,
while profit before tax has increased from Rs.22.77Crore to Rs 37.21
Crore showing increase over63.%of last year.
DIVIDEND
Considering the profits and the need to conserve the resources, your
directors recommend a dividend @ 7% that is 70 paise per share of Rs.
10 each on the paid-up capital of the Company. The outflow on this
account would be Rs 337.61 Lakhs excluding dividend tax.
Consolidated Accounts
In accordance with the requirements of Accounting Standard prescribed
by the Institutreof Chartered Accountants of India, the Consolidated
Accounts for the year ended 31st March 2012 under Indian GAAP forms
part of the Annual Report.
Future outlook
The Company has taken on hand implementation of Betalactum Cepharmand
Ayurvedic projects by utilizing the existing vacant land at
Kakkalur Thiruvellore involving cost outlay of Rs.189.74 Crores. The
projects are expected to be ready for operations by end of current
financial year.
Irrungatukottai unit
The Irrungatukottai unit near Sriperumbudur, Kancheepuram, Tamil Nadu,
is ready for tablets capsules liquid & ointment production and the
remaining sections will be ready by end of Second quarter of the
current year for commencement of operations. The Company propose to get
USFDA approvals for this unit so as to cater the production for
exports.
CHANGES IN CAPITAL STRUCTURE/ CONSOLIDATION
During the current year, with the approval of the shareholders the
equity shares of the company are consolidated by issuing a share of
face value Rs.10 for every ten equity shares of face value of Rs.1
each.
During the current year, the Authorised Share Capital of the Company
has been enhanced from Rs.66 Crores to Rs.70 Crores, to facilitate the
issue of the convertible equity warrants to the promoters and other
body corporates (public) at Rs. 10 each with a premium of Rs.15 per
warrant and the pricing is in accordance with SEBI(SAST) Regulations,
to raise Rs.49.74 Crores. The conversion period is 18 months and on
conversion of all the 19896000 warrants into equity, the paid up share
capital will stand increased to Rs.68.12 Crores.
SUBSIDIARY COMPANY
During the year, Coronet labs P Ltd, has become subsidiary of the
Company. Pursuant to the provision of Section 212 of the Companies Act,
1956, the information on the Subsidiary company are given in this
report.
RESEARCH & DEVELOPMENT:
Arvind Research Centre a sophisticated Research & Development
Laboratory is well equipped with the latest Technologies and Machinery.
The committed R&D team of Research Scientists, Doctors, Ayurvedic
specialists and chemists are the primary driving force in the R&D
Efforts of the Company and the focus areas are Development of Drug
Delivery Systems, New Formulations and Process Development of Various
Dosage forms. The major areas where R&D involved are
(1) Dosage Form/Product Development in allopathic and ayurvedic
segments,
(2) Process development and validation
(3) Analytical method development and validation.
(4) Development Novel drugs delivery development
(5) Nutraceuticals and OTC products special care.
*Dosage Form/Product Development: Headed by strong team leader with
Research scientists and technicians, we apply advances in
pharmaceutical technology to create dosage forms that offer patients
benefit. Our constant mission for developing new products and
technology has to make breakthrough innovations in extensive range of
research areas. Several products with a new delivery system advantage
have earned us a market.
- Mouth Dissolving Tablets
- Modified Release Products
- Dry Powers and Syrups
- Soft Gelatin Capsules
- Skin Care Products
- Sun Care Products
- Sterile Formulation
- Ophthalmic Formulation
'Analytical Method Development: World-class equipments for
Instrumental, Chemical and Microbiological Analysis. Extensive
facilities for establishing the integrity and stability of
pharmaceuticals. Expertise in method development for impurity profiling
and identifying degradation products has been built up. Stability of
products conformed as per ICH guidelines to meet global requirement
*NDDS (Novel Drug Delivery Systems): In the area of NDDS, Arvind
remedies ltd is focused on developing novel drug delivery systems for
anti-infective molecules and NSAID molecules. A few platform and
product specific technologies formulations have been successfully
developed.
The NDDS research at, Arvind remedies ltd focuses on maximizing the
overall therapeutic and commercial value of commonly prescribed
pharmaceutical formulations by enhancing their performance and reducing
their adverse event profile. Such innovation also helps to improve the
overall patient convenience and compliance.
Arvind remedies ltd In-house NDDS programs are primarily focused on the
oral segment. Spray technology and dermal therapy programs are also
being pursued through collaborations.
There is High tech research centre with focus on the core areas of
Diabetology, Cardiology and Nephrology.
In ayurvedic, we have age old Herbal Medicines, Nutraceuticals and anti
infective segments.
The company's in-house R&D unit is recognized by the Department of
Scientific Industrial Research, Ministry of Science and Technology,
Govt, of India.
*R&D Infrastructure, ARL has embarked on R&D in a significant way by
establishing own R&D centre The Company has state-of-the-art
multi-disciplinary centre with dedicated facilities for generics
research and innovative research.
The Pharmaceutical research division covers both the antibiotic and
non-antibiotic segments with specific departments for the Domestic
markets and Regulatory market. New Drug Discovery is objective of our
company, as well we focus on this type of research program.
Intellectual Property Management (IPM):ARL has developed its own
patents/ trade marks for new products of formulations. It has the
system to develop patent applications, potential new products and
markets for new formulations 'Existing Development :ARL has so far
developed more than 250 products which includes products in diabetic,
cardiac, antibiotics, anti allergic sectors.
ARL has developed some formulation products to meet the global market
requirements and mainly meeting with the safety profile, impurity
profiles, dissolution profiles, F1 &F2 Calculations, as perthe
different regulatory norms.
Some of NDDS formulation introduced in pellets formulation for example,
Pantaprazole (delayed release) plus Domperidone immediate release and
sustained release, Tanataprozole also. During the year 2011-12 ARL
developed products for nutritional supplement, treatment of allergic
rhinitis and asthma for kids and anti biotics
Ayurvedic
DST Projects:
A)Obesity induced Hyperlipidemia:
Efforts are made to identify and scientifically validate the
traditional/ indigenous herbs for anti hyperlipidemia, the development
of a novel Polyherbal formulation and for standardization of poly
herbal formulation. It is a collaborative research agreement with Sri
Ramachandra Medical College and Research Institute and Dept. of Science
& Technology, Govt, of India.
Identification and scientific validation studies have been completed;
Formulation study is under progress in the Industrial side. Animal
studies for efficacy is under progress in Institution.
B)Anti Arthritis:
The poly herbal formulation for the treatment of rheumatoid arthritis,
anti arthritis, anti inflammatory, analgesic, Immunomodulatory and
antioxidant with collaborative research agreement with Sri Ramachandra
Medical College and Research Institute and Dept. of Science &
Technology, Govt, of India. Clinical trial is under progress.
C)Anti viral:
Poly herbal formulation for Human Herpes Virus 1, Human Herpes Virus2,
Human Herpes Virus3 and Varicella Zoster. It is a collaborative project
with Presidency College, TNVAS, IIIMand Department of Science and
Technology, Govt, of India.
DIRECTORS
Pursuant to the provisions of Section 256 of the Companies Act, 1956
and the Articles of Association of the Company, Mr. K. V Narayan and
Mr. R Raja Mohan Directors of the Company, retire by rotation at the
ensuing Annual General Meeting and being eligible, offers themselves
for re-appointment. Directors recommend their reappointment.
In accordance with the stipulation under clause 49 of the Listing
Agreement, brief resume of the Directors seeking re- appointment at the
ensuing Annual General Meeting together with the nature of their
expertise in specific functional areas and names of companies in which
they hold office as Director and/or Chairman/ Member of Committees of
the Board is annexed to the notice.
During the year Mr. AnkurAgarwal was appointed as Executive Director
(Tech) from 18th April 2012 and Dr. Raghuveer was appointed as
Executive Director (Operations) from 28th April 2012 for a term of five
years subject to the approval of shareholders in the Annual General
Meeting and these are taken as Special Business at item no.7 & 8 in the
notice.
AUDITORS:
Your company's statutory auditors M/s. Doshi Chatterjee Bagri & Co.
Chartered Accountants, retire at the conclusion of the ensuing Annual
General Meeting. The Statutory Auditors have confirmed their
eligibility and willingness to accept the office on re-appointment. The
necessary resolution seeking approval of members for re-appointment of
Statutory Auditors has been provided in the Notice convening the Annual
General Meeting.
Auditor's Report and Notes to Accounts.
The Board has duly reviewed the Statutory Auditors Report on the
Accounts. The Auditors Report is self explanatory and do not call for
any further explanation/ clarification by the Board of Directors uner
Section 217(3) of the Companies Act, 1956.
Internal Audit
During the year under review, the Company has engaged the services of
M/s.Siva Anantharaman& Co. Chennai, Chartered Accountants, as Internal
Auditors to carry out internal audit on regular basis. The reports of
the Internal audit are presented for review before the Audit Committtee
The Audit Committee also scrutinizes all the programmes and adequacy of
the internal audits.
Management Discussion and Analysis (MDA):
The Management Discussion and Analysis Report for the year under
review, as stipulated under Clause 49 of the Listing Agreement is
presented in a separate section forming part of this Annual Report.
CORPORATE GOVERNANCE
The Company complies with the provisions of Corporate Governance as per
the listing agreement with the Stock Exchanges. Aseparate Report on
Corporate Governance is attached which forms part of the Annual Report.
FIXED DEPOSITS
During the year the Company has not accepted any fixed deposits from
the public.
PARTICULARS OF ENERGY CONSERVATION ETC.
The details of energy conservation, technology absorption, foreign
exchange earning and outgo are furnished in a separate statement
attached to and forming part of this report, in accordance with Section
217(1)(e) of the Companies Act, 1956, read with The Companies
(Disclosure of Particulars in the Report of Board of Directors) Rules,
1988.
PARTICULARS OF EMPLOYEES
During the year, the Company did not have any employee drawing
remuneration of amounts specified under Section 217(2A) of the
Companies Act, 1956, read with The Companies (Particulars of Employees)
Rules, 1975 and hence the details are not furnished.
DIRECTORS' RESPONSIBILITY STATEMENT
Your Directors affirm that the audited accounts containing the
financial statements for the financial year 2011 -12 are in conformity
with the requirements of the Companies Act, 1956. They believe that the
financial statements reflect fairly the form and substance of
transactions carried out during the year and reasonably present the
Company's financial conditions and results of operations.
Pursuance to Section 217(2 AA) of the Companies Act, 1956, your
Directors confirm that -
(i) the annual accounts forthe year ended on 31st March 2012 have been
prepared on a going concern basis
(ii) in preparation of the accounts, the applicable accounting
standards have been followed Necessary explanations are given for
material departures, if any
(iii) sound accounting policies have been applied consistently and
judgements and estimates made that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company as on
31st March 2012 and of the Profit of the company fro the year ended on
that date and
(iv) proper and sufficient care has been taken for maintenance of
adequate accounting records in accordance with the provisions of the
Companies Act, 1956 for safeguarding the assets of the company and for
prevention and detection of fraud and other irregularities.
INTERNAL AUDIT AND CONTROL
The Company has a proper and adequate system of internal control. The
internal auditor verifies the records and furnishes his report to the
Management for onward submission to the Statutory Auditors. There is an
Audit Committee consisting of non-executive Directors as members. The
Audit Committee periodically reviews the internal control systems.
LISTING:
The Company's shares are presently listed at Bombay Stock Exchange Ltd.
and in National Stock Exchange of India Ltd.
ACKNOWLEDGEMENTS
Your Directors wish to place on record their appreciation for the
continued co-operation of the banks and other financial institutions
associated with the company. Your Directors also thank Medical
fraternity for the trust reposed on the Company and the trade, the
stockists and consumers for their patronage to the Company's products.
Your Directors also place on record their profound admiration and
sincere appreciation of the continued hard work put in by the employees
at all levels. We look forward to the same support in our future
endeavors.
For and on behalf of the Board
Arvind Remedies Ltd.
Dr. B. ARVIND SHAH Dr.CHANDRARAVINDRAN
Date : 30.05.2012 Managing Director Whole time Director
Mar 31, 2011
Dear Members,
The Directors have pleasure in presenting the Twenty-Third Annual
Report together with the Audited Statement of Accounts for the year
ended March 31, 2011
FINANCIAL RESULTS (Rs. in Crores)
Particulars 2010-2011 2009-2010
Gross Income 368.79 303.74
Profit before tax 22.77 15.34
Profit after tax 16.90 10.64
Profit available for appropriation
(after considering
the balance b/f from previous year
and deferred tax liability) 42.36 28.04
APPROPRIATION
Dividend 2.18 1.30
Corporate Dividend Tax 0.35 0.22
Transfer to General Reserve 1.69 1.06
Operations and Business Performance
During the year 2010-11, the sales increased from Rs.309.24 Crore to
Rs.376.89 Crores, recording an increase of 22% over the previous year,
while profit before tax has increased from Rs.15.34 Crore to Rs.22.77
Crore showing increase of 48% over last year.
DIVIDEND
Considering the profits and the need to conserve the resources, your
directors recommend a dividend of 7 paise per share of Rs.1 each on pro
rata basis on the paid-up capital of the Company. The outflow on this
account would be Rs 2.18 Crores excluding dividend tax.
FUTURE OUTLOOK
The Company has updated existing Kakkalur plant in accordance with
revised Schedule M specifications.
IRRUNGATUKOTTAI UNIT
The Irrungatukottai unit near Sriperumbudur, Kancheepuram, Tamil Nadu,
is under implementation and is expected to be ready by this year end
for commercial operations. The Company propose to get USFDA approvals
for this unit so as to cater to the production for exports.
RESEARCH & DEVELOPMENTS:
Arvind Research Centre a sophisticated Research & Development
Laboratory is well equipped with the latest Technologies and Machinery.
The committed R&D team of 12 Research Scientists, Doctors, Ayurvedic
specialists and chemists are the primary driving force in the R&D
Efforts of the Company and the focus areas are Development of Drug
Delivery Systems, New Formulations and Process Development of Various
Dosage forms. The major areas where R&D involved are
(1) Dosage Form/Product Development in allopathic and ayurvedic
segments,
(2) Process development and validation
(3) Analytical method development and validation.
(4) Development of Novel Drugs Delivery System.
(5) Nutraceuticals and OTC products special care.
*Dosage Form/Product Development: Headed by strong team leader with 15
Research scientists and technicians, we apply advancement in
pharmaceutical technology to create dosage forms that offer patients
benefit. Our constant mission for developing new products and
technology has to make breakthrough innovations in extensive range of
research areas. Several products with a new delivery system advantage
have earned us a market
- Mouth Dissolving Tablets
- Modified Release Products
- Dry Powers and Syrups
- Soft Gelatin Capsules
- Skin Care Products
- Sun Care Products
- Sterile Formulation
- Ophthalmic Formulation
*ANALYTICAL METHOD DEVELOPMENT : World-class equipments for
Instrumental, Chemical and Microbiological Analysis. Extensive
facilities for establishing the integrity and stability of
pharmaceuticals. Expertise in method development for impurity
profiling and identifying degradation products has been built up.
Stability of products conformed as per ICH guidelines to meet global
requirement
*NDDS (Novel Drug Delivery Systems) : In the area of NDDS, Arvind
remedies ltd is focused on developing novel drug delivery systems for
anti-infective molecules and NSAID molecules. A few platform and
product specific technologies formulations have been successfully
developed. The NDDS research at, Arvind remedies ltd focuses on
maximizing the overall therapeutic and commercial value of commonly
prescribed pharmaceutical formulations by enhancing their performance
and reducing their adverse event profile. Such innovation also helps to
improve the overall patient convenience and compliance.
Arvind remedies ltd In-house NDDS programs are primarily focused on the
oral segment. Spray technology and dermal therapy programs are also
being pursued through collaborations.
There is High tech research center with focus on the core areas of
Diabetology, Cardiology and Nephrology.
In ayurvedic, we use age old Herbal Medicines, Nutraceuticals and anti
infective segments.
The company's in-house R&D unit is recognized by the Department of
Scientific Industrial Research, Ministry of Science and Technology,
Govt. of India.
*R&D INFRASTRUCTURE, ARL has embarked on R&D in a significant way by
establishing own R&D centre The Company has state-of-the-art
multi-disciplinary centre with dedicated facilities for generics
research and innovative research.
The Pharmaceutical research division covers both the antibiotic and
non-antibiotic segments with specific departments for the Domestic
markets and Regulatory market. New Drug Discovery is objective of our
company, as soon we focus on this type of research program.
*INTELLECTUAL PROPERTY MANAGEMENT (IPM):ARL has developed its own
patents/ trade marks for new products of formulations. It has the
system to develop patent applications, potential new products and
markets for new formulations
*Existing Development :ARL has so far developed more than 250 products
which includes products in diabetic, cardiac, antibiotics, anti
allergic sectors.
ARL has developed some formulation products to meet the global market
requirements and mainly meeting with the safety profile, impurity
profiles, dissolution profiles, F1&F2 Calculations, as per the
different regulatory norms.
Some of NDDS formulation introduced in pellets formulation for example,
Pantaprazole (delayed release) plus Domperidone immediate release and
sustained release, Tanataprozole also.
AYURVEDIC - DST PROJECTS:
A) OBESITY INDUCED HYPERLIPIDEMIA:
Efforts are made to identify and scientifically validate the
traditional/ indigenous herbs for anti hyperlipidemia, the development
of a novel Polyherbal formulation and for standardization of poly
herbal formulation. It Is a collaborative research agreement with Sri
Ramachandra Medical College and Research Institute and Dept. of Science
& Technology, Govt. of India.
Identification and scientific validation studies have been completed;
Formulation study is under progress in the Industrial side. Animal
studies for efficacy is under progress in Institution.
B) ANTI ARTHRITIS:
The poly herbal formulation for the treatment of rheumatoid arthritis,
anti arthritis, anti inflammatory, analgesic, Immunomodulatory and
antioxidant with collaborative research agreement with Sri Ramachandra
Medical College and Research Institute and Dept. of Science &
Technology, Govt. of India. Clinical trial is under progress.
C) ANTI VIRAL:
Poly herbal formulation for Human Herpes Virus 1, Human Herpes Virus2,
Human Herpes Virus3 and Varicella Zoster. It is a collaborative project
with Presidency College, TNVAS, IIIM and Department of Science and
Technology, Govt. of India.
FUTURE PLANS
ALLOPATHIC
The company is focused on NDDS segment to tap and fulfill the global
markets with safety and efficacy. From this segment the company is
looking into the feasibility to develop Topical formulation,
Parenteral, Ophthalmic, Pellatization of products in different
formulation and Tablets & Capsules
To initiate the soft gelatin formulation to stabilize the enzymes and
Multivitamin products in nutritional segment for global and domestic
markets.
To develop full-fledged separate CONTRACT RESEARCH in future.
To develop US-FDA ,MHRA,TGA,ANVISA approved Formulation in all major
areas.
To develop New Drug Discovery department, as soon we focus on this type
of research program.
AYURVEDA
1. Ayurvedic Plant construction is under progress.
2. Development of Range of Products is under progress, we are mainly
concentrating on the chronic ailments, presently uterine tone,
Aphrodisiac, Hepato-protective products Development for the present.
DIRECTORS
Pursuant to the provisions of Section 256 of the Companies Act, 1956
and the Articles of Association of the Company, Dr. C.M K Reddy,
Director of the Company, retires by rotation at the ensuing Annual
General Meeting and being eligible, offers himself for re-appointment.
Directors recommend his reappointment.
In accordance with the stipulation under clause 49 of the Listing
Agreement, brief resume of the Director seeking re-appointment at the
ensuing Annual General Meeting and names of companies in which holds
office as Director and/or Chairman/ Member of Committees of the Board
is given in annexure to the notice.
During the year, Mr. Prakash Shah, resigned from 5th January 2011. Mr.
Akshay Shah who was appointed as Additional Director from 5th January
2011 resigned on 2nd July 2011. Board places on record deep sense of
appreciation for the valuable services rendered by them during their
tenure as Directors of the Company.
During the year Mr. R. Raja Mohan from 13th November 2010 and Mr.V. R
Mehta from 5th January 2011 were appointed as Additional Directors
pursuant to Section 260 of the Companies Act, 1956 and their term will
expire at the conclusion of the ensuing Annual General Meeting. The
Company has received nominations from members proposing them to be
elected as Directors of the Company and pursuant to Section 257 of the
Companies Act, 1956, Board recommends to pass the special resolution
nos. 5 & 6 given in the Notice.
AUDITORS:
Your company's Statutory Auditors M/s. Doshi Chatterjee Bagri & Co.
Chartered Accountants, retired at the conclusion of the ensuing Annual
General Meeting. The Statutory Auditors have confirmed their
eligibility and willingness to accept the office on re-appointment. The
necessary resolution seeking approval of members for re-appointment of
Statutory Auditors has been provided in the Notice convening the Annual
General Meeting.
AUDITOR'S REPORT AND NOTES TO ACCOUNTS.
The Board has duly reviewed the Statutory Auditors Report on the
Accounts. The Auditors Report is self explanatory and do not call for
any further explanation/ clarification by the Board of Directors uner
Section 217(3) of the Companies Act, 1956.
INTERNAL AUDIT
During the year under review, the Company has engaged the services of
M/s.Siva Anantharamn & Co. Chartered Accountants, Chennai as Internal
Auditors to carry out internal audit on regular basis. The reports of
the Internal audit are [presented for review before the Audit
Committtee The Audit Committee also scrutinizes all the programmes and
adequacy of the internal audits.
APPOINTMENT OF CHIEF FINANCIAL OFFICER
During the year the Company has appointed Mr. S.V Sundara Raman as
Chief Financial Officer who has joined on 30th December 2010.Mr.
Sundara Raman is having vast experience of 32 years prior to joining
the company.
MANAGEMENT DISCUSSION AND ANALYSIS (MDA):
The Management Discussion and Analysis Report for the year under
review, as stipulated under Clause 49 of the Listing Agreement is
presented in a separate section forming part of this Report.
CORPORATE GOVERNANCE
The Company complies with the provisions of Corporate Governance as per
the listing agreement with the Stock Exchanges. A separate Report on
Corporate Governance is attached which forms part of the Annual Report.
FIXED DEPOSITS
During the year the Company has not accepted any fixed deposits from
the public.
PARTICULARS OF ENERGY CONSERVATION ETC.
The details of energy conservation, technology absorption, foreign
exchange earning and outgo are furnished in a separate statement
attached to and forming part of this report, in accordance with Section
217(1)(e) of the Companies Act, 1956, read with The Companies
(Disclosure of Particulars in the Report of Board of Directors) Rules,
1988.
PARTICULARS OF EMPLOYEES
During the year, the Company did not have any employee drawing
remuneration of amounts specified under Section 217(2A) of the
Companies Act, 1956, read with The Companies (Particulars of Employees)
Rules, 1975 and hence the details are not furnished.
DIRECTORS' RESPONSIBILITY STATEMENT
Your Directors affirm that the audited accounts containing the
financial statements for the financial year 2010-11 are in conformity
with the requirements of the Companies Act, 1956. They believe that the
financial statements reflect fairly the form and substance of
transactions carried out during the year and reasonably present the
Company's financial conditions and results of operations.
Pursuance to Section 217(2 AA) of the Companies Act, 1956, your
Directors confirm that Ã
(I) the annual accounts for the year ended on 31st March 2011 have been
prepared on a going concern basis
(ii) in preparation of the accounts, the applicable accounting
standards have been followed Necessary explanations are given for
material departures, if any
(iii) sound accounting policies have been applied consistently and
judgements and estimates made that are reasonable and prudent so as to
give a true and fair view of the state of affairs of the company as on
31st March 2011 and of the Profit of the company for the year ended on
that date and
(iv) proper and sufficient care has been taken for maintenance of
adequate accounting records in accordance with the provisions of the
Companies Act, 1956 for safeguarding the assets of the company and for
prevention and detection of fraud and other irregularities.
INTERNAL AUDIT AND CONTROL
The Company has a proper and adequate system of internal control. The
internal auditor verifies the records and furnishes his report to the
Management for onward submission to the Statutory Auditors. There is
an Audit Committee consisting of non-executive Directors as members.
The Audit Committee periodically reviews the internal control systems.
LISTING:
The Company's shares are presently listed at Bombay Stock Exchange Ltd.
and in National Stock Exchange of India Ltd.
ACKNOWLEDGEMENTS
Your Directors wish to place on record their appreciation for the
continued co-operation of the banks and other financial institutions
associated with the company. Your Directors also thank Medical
fraternity for the trust reposed on the Company and the trade, the
stockists and consumers for their patronage to the Company's products.
Your Directors also place on record their profound admiration and
sincere appreciation of the continued hard work put in by the employees
at all levels. We look forward to the same support in our future
endeavours.
For and on behalf of the Board
Dr. B. ARVIND SHAH Dr. CHANDRA RAVINDRAN
Managing Director Whole time Director
Place : Chennai
Date : 23.05.2011
Mar 31, 2010
The Directors have pleasure in presenting the Twenty-Second Annual
Report together with the Audited Statement of Accounts for the year
ended March 31, 2010
FINANCIAL RESULTS (Rs. in Crores)
Particulars 2009-2010 2008-2009
Gross Income 303.74 218.87
Profit before tax 15.34 7.17
Profit after tax 10.64 4.82
Profit available for appropriation
(after considering the balance b/f
from previous year and deferred tax
liability) 28.04 19.41
APPROPRIATION
Dividend 1.30 1.30
Corporate Dividend Tax 0.22 0.22
Transfer to General Reserve 1.06 0.48
Surplus carried to Balance Sheet 25.46 17.40
Operations and Business Performance
During the year 2009-10, the sales increased from Rs.229.21Crore to Rs
309.24 Crores, recording an increase of 35% over the previous year,
while profit before tax has increased from Rs.7.17 Crore to Rs 15.34
Crore.
DIVIDEND
Considering the profits and the need to conserve the resources, your
directors recommend a dividend of 5 paise per share of Re.1 each on the
paid-up Equity share capital of the Company. The outflow on this
account would be Rs.130.02 Lakhs.
FUTURE OUTLOOK
Looking to the global and domestic scenario of pharma industry the
company wanted to explore the possibilities to venture especially in
the injectibles and soft gelatine sector, which will benefit in terms
of more business. The Company plans to utilize the existing vacant land
at Kakkalur for Ayurvedic plant and Betalactum plant.
Haridwar Project
During the year the company disposed of the Haridwar Unit and paid back
the term loan and unsecured loan taken for the project, out of the
proceeds of sale.
New Unit at Irrungatukottai
Your company for the new unit at Irrungatukottai, Tamil Nadu, has tied
up the funds requirement and the building construction is in progress.
The unit is expected to be ready by September 2011 for commercial
production after which the manufacturing of injectibles and soft jel
could be commenced.
RESEARCH & DEVELOPMENTS:
Arvind Research Centre a sophisticated Research & Development
Laboratory is well equipped with the latest Technologies and Machinery.
The committed R&D team of 10 Research Scientists, Doctors, Ayurvedic
specialists and chemists are the primary driving force in the R&D
Efforts of the Company and the focus areas are Development of Drug
Delivery Systems, New Formulations and Process Development of Various
Dosage forms. The six major areas where R&D involed are (1) formulation
development in ayurvedic and (2) allopathic segments, (3) Process
development and validation (4) Novel drugs delivery development (5)
Nutraceuticals and (6) Analytical Development.
There is High tech research center which focuses on the core areas of
Diabetology, Cardiology and Nephrology using age old Herbal Medicines,
Nutraceuticals and anti infective segments. The companys in-house R&D
unit is recognized by the Department of Scientific Industrial Research,
Ministry of Science and Technology, Govt. of India.
R&D Infrastructure,
ARL has embarked on R&D in a significant way by establishing own R&D
centre The Company has state- of-the-art multi-disciplinary centre with
dedicated facilities for generics research and innovative research.
Novel Drug Delivery Systems (NDDS),
The area will be on developing novel drug delivery systems for
anti-infective molecules and NSAID molecules. A few platform and
product specific technologies formulations have been successfully
developed.
In research, efforts will be on maximizing the overall therapeutic and
commercial value of commonly prescribed pharmaceutical formulations by
enhancing their performance and reducing their adverse event profile.
Such innovation also helps to improve the overall patient convenience
and compliance.
The focus is mainly on the development of Abbreviated New Drug
Applications (ANDAs) of oral controlled- release products for the
regulated markets. The Companys In-house NDDS programs are primarily
focused on the oral segment. Spray technology and dermal therapy
programs are also being pursued through collaborations.
Intellectual Property Management (IPM)
ARL has developed its own patents/ trade marks for new products of
formulations. It has the system to develop patent applications,
potential new products and markets for new formulations
Existing Developments
The Company has developed Poly Herbal Formulations. It Concentrates on
chronic ailments and for treatment in anti arthritic formulation,
obesity induced hyperlipidemia and anti viral for human herpes virus 1
and 2 and varicellazoste These are handled with Dept of Science and
Technology, Govt. of India and Sri Ramachandra University, Chennai.
ARL has so far developed more than 200 products which includes products
in diabetic, cardiac, antibiotics and anti allergic sectors. Some of
the recently developed products are Montelukast and Ondensatran (mouth
dissolving tablets) and Montelukast with Levocitrizine (mouth
dissolving form ) for first time in India.
ARL has developed some formulation products to meet the global market
requirements and meeting with the safety profile, impurity profiles,
dissolution profiles, F1&F2 Calculations, as per the different
regulatory norms.
Some of NDDS formulations are introduced in pellets, for example,
Pantaprazole (delayed release) plus Domperidone immediate release and
sustained release, Tanataprozole.
Future Plans
Ayurveda
Patent filing, Clinical trial Phase II, Safety and efficacy studies,
Going for separate plant Formulate and develop nutritional supplements
in herbal preperations for international markets.
Allopathy
The company is focused on NDDS segment to tap and fulfill the global
markets with safety and efficacy. From this segment the company is
looking into the feasibility to develop Topical formulation,
Parantarals, Ophthalmic, Pellatization of products in different
formulations and also Tablets & Capsules
To initiate the soft gelatin formulation to stabilize the enzymes and
Multivitamin products in nutritional segment for global and domestic
markets.
To develop full-fledged separate Analytical department to support the
Formulation development.
To develop US-FDA approved NDA Formulation in all major areas.
DIRECTORS
Pursuant to the provisions of Section 256 of the Companies Act, 1956
and the Articles of Association of the Company, Mr. K. V Narayanan,
Director of the Company, retires by rotation at the ensuing Annual
General Meeting and being eligible, offers himself for re-appointment.
During the year, Dr. Yogesh Kothari, who was appointed as Additional
Director, resigned from 7th September 2009. Board places on record deep
sense of appreciation for the valuable services rendered by him during
his tenure as Director of the Company.
Resignation of Chief Financial Officer
During the year Mr. Kuppu Dhandapani, Chief Financial Controller
resigned from the services of the Company from 18th March 2010. The
Company is in look out of suitable person to fill the position.
CORPORATE GOVERNANCE
The Company complies with the provisions of Corporate Governance as per
the listing agreement with the Stock Exchanges. A separate Report on
Corporate Governance is attached which forms part of this Annual
Report.
FIXED DEPOSITS
During the year the Company has not accepted any fixed deposits from
the public.
PARTICULARS OF ENERGY CONSERVATION ETC.
The details of energy conservation, technology absorption and foreign
exchange earning and outgo are furnished in a separate statement
attached to and forming part of this report, in accordance with Section
217(1)(e) of the Companies Act, 1956, read with The Companies
(Disclosure of Particulars in the Report of Board of Directors) Rules,
1988.
PARTICULARS OF EMPLOYEES
During the year, the Company did not have any employee drawing
remuneration of amounts specified under Section 217(2A) of the
Companies Act, 1956, read with The Companies (Particulars of Employees)
Rules, 1975 and hence the details are not furnished.
DIRECTORS RESPONSIBILITY STATEMENT
In pursuance of Section 217(2 AA) of the Companies Act, 1956, your
Directors confirm Ã
(i) that in the preparation of the annual accounts, the applicable
accounting standards have been followed along with proper explanation
relating to material departures;
(ii) that the Directors had selected such accounting policies and
applied them consistently and made judgments and estimates that were
reasonable and prudent so as to give a true and fair view of the state
of affairs of the Company at the end of the financial year and of the
profit or loss of the Company for that period;
(iii) that the Directors had taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the
provisions of this Act, for safeguarding the assets of the Company and
for preventing and detecting fraud and other irregularities;
(iv) that the Directors had prepared the annual accounts on a going
concern basis.
AUDITORS
The Statutory Auditors M/s Doshi, Chatterjee, Bagri & Co, Chartered
Accountants shall retire at the ensuing Annual General Meeting and have
confirmed their eligibility and willingness to accept the same
position, if re-appointed.
INTERNAL AUDIT AND CONTROL
The Company has a proper and adequate system of internal control. The
internal auditor verifies the records and furnishes his report to the
Management for onward submission to the Statutory Auditors. There is
an Audit Committee consisting of non-executive Directors as members.
The Audit Committee periodically reviews the internal control systems.
LISTING:
The Companys shares are presently listed at Bombay Stock Exchange Ltd.
and in National Stock Exchange of India Ltd.
ACKNOWLEDGEMENTS
Your Directors wish to place on record their appreciation for the
continued co-operation of the banks and financial institutions
associated with the company. Your Directors also thank Medical
fraternity for the trust reposed on the Company and the trade, the
stockists and consumers for their patronage to the Companys products.
Your Directors also place on record their profound admiration and
sincere appreciation for the continued hard work put in by the
employees at all levels. We look forward to the same support in our
future endeavours.
For and on behalf of the Board
Place : Chennai Dr. B. ARVIND SHAH Dr. CHANDRA RAVINDRAN
Date : 31.08.2010 Managing Director Whole time Director
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article